Market evolution: Cyclic amides (CN 292429) — 2015–2025

Introduction

CN 292429 covers a broad residual category of cyclic amides, including cyclic carbamates and their derivatives (excluding ureines, N-acetylanthranilic acid, ethinamate, and alachlor). This product family is deeply embedded in the organic chemicals value chain, serving as intermediates for pharmaceuticals, agrochemicals, and specialty materials. Over the period 2015–2025, the EU's external trade in this product class underwent a pronounced transformation: unit values more than doubled while traded volumes contracted sharply, supplier geographies shifted decisively towards Asia, and EU domestic production roughly doubled in value terms. This report examines those dynamics across three thematic dimensions.

1. Price escalation and volume compression restructure EU trade flows

Export values held steady even as volumes nearly halved

Between 2015 and 2025, EU extra-EU exports of CN 292429 grew marginally in value terms (+1.8%, from €496 million to €504 million), yet export volumes fell by almost half (–49.6%, from 13,288 tonnes to 6,702 tonnes). The mechanism bridging this gap was a dramatic rise in unit export prices, which doubled from €37,276/t to €75,108/t (+101.5%). The data for the main sub-line (29242970, cyclic amides excluding lidocaine) shows that export unit values accelerated notably from 2022 onward, rising from €40,553/t in 2021 to €75,698/t in 2025.

Source: General Overview

Imports followed the same pattern but with a distinct timing

EU import volumes declined by 21.2% (from 50,186 to 39,566 tonnes), yet import values rose by 21.5% to reach €2,031 million by 2025. The unit-price increase was smaller than on the export side (+54.0%), but the absolute value base was much larger. A particularly sharp import-price jump occurred between 2023 and 2024: the unit value for sub-line 29242970 surged from approximately €33,420/t to €53,434/t, a single-year increase of roughly 60%. This jump likely reflects a combination of product-mix shifts towards higher-value derivatives, post-COVID cost pass-through in the chemical sector, and tighter supply conditions.

The trade deficit widened despite falling volumes

The EU's trade deficit in cyclic amides deepened from –€1,176 million in 2015 to –€1,526 million in 2025 (–29.7%). Because import values grew faster than export values while both volumes shrank, the EU is increasingly a net buyer of higher-priced cyclic amide products. However, net import reliance actually improved from 70.6% to 54.3%, suggesting that rising EU domestic production (discussed in Section 3) has partially offset the trade imbalance in volume terms.

2. A structural reorientation of supplier and buyer geographies

Switzerland's dominance in EU imports collapsed; China and India surged

The most striking geographic shift on the import side was the decline of Switzerland and the rise of China and India. In 2015, Switzerland was the EU's largest supplier of CN 292429, accounting for over €1,004 million — more than 60% of all extra-EU imports. By 2025, Swiss imports had fallen by 68.4% to €317 million. Over the same period, China's share exploded from €187 million to €796 million (+325.5%), making it the EU's top supplier. India grew even more rapidly in percentage terms (+319%, from €85 million to €354 million), while imports from the United States and Norway also expanded substantially.

Source: Top partners by value

The United Kingdom's imports into the EU virtually disappeared (–95.2%), falling from €67.7 million to just €3.3 million — a development consistent with post-Brexit trade barriers and reclassification of trade flows. The import HHI dropped from 3,977 to 2,392 (–39.8%), confirming that import supply became meaningfully more diversified over the decade.

EU export destinations shifted towards the US, Russia, and Japan

On the export side, the United States remained the EU's largest single buyer, growing from €110 million to €213 million (+94.0%). Russia saw the most dramatic increase, surging from €3.7 million to €39.5 million (+954%), likely reflecting pharmaceutical intermediate demand. Japan nearly doubled to €56.9 million. Conversely, Canada experienced a steep decline (–80.3%, from €67.3 million to €13.3 million), and export destinations became moderately more concentrated, with the export HHI rising from 1,569 to 2,120 (+35.1%).

Price volatility was highest in smaller or geopolitically sensitive trade corridors

The coefficient of variation of import values reveals that the United Kingdom (CV = 0.96) and Hong Kong (CV = 1.08) exhibited the most volatile import flows — consistent with the collapse or irregularity of trade with those partners. Among major suppliers, the United States (CV = 0.34) and Japan (CV = 0.32) showed moderate volatility. On the export side, Russia (CV = 0.57) and Canada (CV = 0.56) stood out as the most volatile destinations. Three notable supply shocks were detected: a major price spike in EU exports to the United States in 2019 (abnormality score 112.1, +157.4% unit-price shift), a price shock in exports to Mexico in 2023 (+395.1%), and an import-price shock from India in 2019 (+241.4%).

3. EU domestic production surges amid shifting member-state roles

EU production roughly doubled in both volume and value

According to PRODCOM production data, EU domestic production of cyclic amides (PRODCOM 21102070) grew from 9,451 tonnes / €432 million to an estimated 20,000 tonnes / €1,200 million over the period — an increase of 111.6% in volume and 177.8% in value. This expansion helps explain the declining net import reliance (from 70.6% to 54.3%) and the falling trade intensity ratio (from 98.9% to 77.4%). The EU is producing more cyclic amides domestically and relying somewhat less on external supply, even though the absolute trade deficit widened because of price effects.

Ireland overtook Germany as the EU's largest importer

Within the EU, the geography of imports shifted substantially. Germany remained the largest EU importer in 2015 (€697 million), but its share fell by 47.1% to €368 million by 2025. Ireland, by contrast, more than doubled its imports from €299 million to €717 million (+139.5%), making it the largest EU importer by 2025. This likely reflects the growth of Ireland's pharmaceutical manufacturing sector, which is a major consumer of cyclic amide intermediates. France also saw a significant contraction (–46.9%, from €175 million to €93 million), while Italy grew modestly (+19.1%).

Source: Top reporters by value

Specialisation is concentrated in Italy, Ireland, and Belgium

The revealed comparative advantage (RCA) data for 2025 shows that Italy (RCA = 5.33, RSCA = 0.68) is by far the most specialised EU exporter of cyclic amides, accounting for 42.7% of EU production value but only 8.0% of total EU exports — indicating it is a major producer oriented partly towards the internal market. Ireland (RCA = 2.71) and Belgium (RCA = 1.62) also display significant specialisation. Among the top three EU exporters, Germany and Italy both saw declining export values (–2.3% and –24.2% respectively), while France experienced a dramatic surge from near-zero in 2015 to €76.6 million in 2025, establishing itself as a significant new EU exporter.

Lidocaine remains a niche but stable sub-segment

The sub-line 29242910 (lidocaine) represents a small share of total trade. EU imports of lidocaine ranged between 27 and 84 tonnes per year, while exports fluctuated between 215 and 382 tonnes. Lidocaine export prices were consistently higher than those of the broader cyclic amides category (ranging from €35,000/t to €64,500/t), consistent with its status as a pharmaceutical active ingredient. The stability of this sub-segment contrasts with the more volatile dynamics observed in the broader product group.

Conclusion

Over the 2015–2025 period, the EU's external trade in cyclic amides (CN 292429) has been shaped by three reinforcing dynamics: (1) a pervasive price escalation that doubled unit export values and increased import prices by over 50%, masking declines in traded volumes; (2) a decisive geographic reorientation, most notably the collapse of Switzerland as the dominant supplier and the rise of China and India to account for a combined €1,150 million in EU imports; and (3) a significant expansion of EU domestic production, which has helped reduce net import reliance from 71% to 54%, even as the nominal trade deficit widened to over €1.5 billion. The concentration of import supply has decreased (HHI –40%), while export destinations have become moderately more focused. Going forward, the combination of rising Asian supplier dominance, Ireland's growing role as a processing hub, and continued price inflation will be the key structural features to monitor in this market.